Loading companies…
TT
Tempo Therapeutics
United States · Biotech · Healthtech
A regenerative-medicine company developing injectable microporous scaffolds that help the body rebuild tissue at damaged sites.
A material scaffold for tissue repair
Tempo's MAP technology uses microporous annealed particles to form synthetic scaffolds that can be delivered into a wound or tissue defect. The scaffold's physical microenvironment is designed to encourage local immune activity associated with regeneration rather than scar formation.
A platform in development
Its lead product, TT101, is a cell-free material intended for regenerative biosurgery. The MAP platform can also be combined with controlled-release approaches, including small molecules or stem cells. Tempo is developing the technology for tissue repair and regenerative medicine; its product candidates are investigational.
Funding history
1 round · 1 with disclosed amounts| Announced | Round | Amount | Investors |
|---|---|---|---|
| Funding | $14.5M | Galaxy Sirius Partners — ParticipantGideon Strategic Partners — ParticipantJohnson & Johnson Innovation – JJDC, Inc. — ParticipantMesa Verde Venture Partners — ParticipantYK Bioventures — Participant |
Investors
Galaxy Sirius PartnersJoined FundingGideon Strategic PartnersJoined FundingJohnson & Johnson Innovation – JJDC, Inc.Joined FundingMesa Verde Venture PartnersJoined FundingYK BioventuresJoined FundingCoverage
Sep 18, 2026Tempo Therapeutics · FundingSimilar companies
GMGeneral MedicineAn online healthcare store where people compare care options and upfront prices, book visits and order medications or lab tests.$120M · Series B
AnaCardioAnaCardio is a clinical-stage biopharmaceutical company developing medicines intended to improve heart muscle function in people with heart failure.€62.5M · Series B
AventixAventix builds sensor-based analytical instruments for laboratories. Its first product, Scarlett 01, measures liquid volumes across microplate wells without touching the sample, helping R&D teams check dispensing quality and catch volume variation before it affects assay results.€1.2M · Pre-seed